![](https://investorshub.advfn.com/uicon/521970.png?cb=1579207683)
Tuesday, November 09, 2021 7:20:59 AM
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) has entered into a definitive agreement with Eli Lilly and Company which allows Regen to receive compounds from Lilly for drug discovery purposes and allows Regen to share structural information on compounds of mutual interest.
The agreement also grants to Lilly an option to negotiate an agreement with Regen including but not restricted to a compound purchase agreement, a license agreement, or a research collaboration agreement for further research and development of material of mutual interest.
"Lilly's Open Innovation Drug Discovery Program is visionary," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen BioPharma, Inc. "They understand the value of partnering in a confidential manner with smaller entities that may have intellectual property that aligns with their product goals."
As a consequence of this agreement, Regen will examine 21,000 Lilly-owned compounds in its NR2F6 high-throughput screening program as it attempts to identify activators and inhibitors of this protein. Regen will share the experimental data with Lilly and the two companies will jointly decide on next steps.
NR2F6 is a molecular switch known as an "orphan nuclear receptor," which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate. Regen has filed numerous patents covering means of manipulating NR2F6 in oncology and immunology. Issued US Patent # 9091696 was granted to Regen and covers means of screening small molecules such as is being done in this program. Cancer, as well as autoimmune diseases such as lupus, rheumatoid arthritis and irritable bowel syndrome, is likely to be controlled by modifying NR2F6 activity.
Regen is currently in the process of screening more than 70,000 compounds in an effort to identify activators and inhibitors of NR2F6. Two activators have been identified and preliminary work on inhibitors is currently underway.
https://www.biospace.com/article/releases/regen-biopharma-enters-into-open-innovation-drug-discovery-program-agreement-with-eli-lilly-/
The result of this collaboration will prove to be Historic. EOM.
Sometimes its Skil, Sometimes its Luc.
I Appreciate All Member Follows!
Desperate Sellers Become Desperate Buyers. Vice Versa
ALL IMHO.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM